Immediate Impact
3 by Nobel laureates 1 from Science/Nature 56 standout
Citing Papers
Fluorescent Probes for Disease Diagnosis
2024 Standout
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 Standout
Works of Volker Moebus being referenced
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
2021
Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Volker Moebus | 390 | 222 | 95 | 161 | 52 | 692 | |
| M.R. Sertoli | 433 | 104 | 72 | 120 | 33 | 625 | |
| Maki Tanioka | 319 | 156 | 106 | 251 | 73 | 766 | |
| Sally Baron‐Hay | 365 | 109 | 68 | 231 | 44 | 734 | |
| Loredana Miglietta | 283 | 135 | 114 | 141 | 47 | 587 | |
| Rong‐Miao Zhou | 288 | 222 | 72 | 448 | 59 | 843 | |
| J P Basuyau | 224 | 136 | 138 | 105 | 33 | 605 | |
| Evangelos Bournakis | 265 | 150 | 159 | 267 | 34 | 610 | |
| Kenichi Harano | 376 | 88 | 124 | 113 | 63 | 657 | |
| Tomoyo Yasui | 186 | 154 | 66 | 255 | 57 | 605 | |
| U. Klaassen | 634 | 197 | 128 | 115 | 31 | 769 |
All Works
Loading papers...